Announcements Trials
Browse Landscape

Phase

Phase NA 66Phase 2 8Phase 1 7Phase 4 2Phase 3 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Motor Activity 1Insulin Resistance 1Body Weight 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Diet Therapy × Clear all
NCT06954584 2025-06-24

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

Tongji Hospital

Phase 3 Recruiting
424 enrolled
Gynecologic

Ovarian Neoplasms

NCT01482286 2022-03-15

PULSE

Pennington Biomedical Research Center

Phase 3 Terminated
32 enrolled 10 charts

Body Weight, Insulin Resistance, Motor Activity, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡